# Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)

> **NCT03018340** · PHASE2 · COMPLETED · sponsor: **ACADIA Pharmaceuticals Inc.** · enrollment: 207 (actual)

## Conditions studied

- Adjunctive Treatment of Major Depressive Disorder

## Interventions

- **DRUG:** Pimavanserin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03018340
- **Lead sponsor:** ACADIA Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2018-09
- **Final completion:** 2018-10
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2019-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03018340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03018340, "Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03018340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*